ABB Robotics earlier this week announced it has teamed up with biotechnology company Vyripharm Enterprises Inc. to develop an automated laboratory testing platform.
The companies said the platform will be used for quality control of raw material to novel pharmaceutical compounds.
This fully automated robotic platform will be the first of its kind and will support the capture of data for use in research and development efforts within industry and health institutions, the companies said.
Under the terms of the partnership, VEI will provide process definition, intellectual property (IP), equipment, software, and associated funds. ABB will provide automation software and robotics to show the operational function of the integrative platforms. Two beta sites, located in Texas and Colorado, are currently under construction and are expected to be operational in 2023, with other locations planned throughout the U.S. and internationally.
ABB opened a facility dedicated to health care research in 2019
In 2019, ABB opened its first dedicated global life sciences and health care research facility (ABB Life Sciences and Healthcare Solutions), in the Texas Medical Center (TMC) Innovation Institute. ABB Life Sciences and Healthcare Solutions hopes to bring advancement to the life sciences and healthcare industries, covering pharmaceutical and medical device production, and laboratory automation.
ABB Robotics said it collaborates with the medical community to co-develop automation technologies that help hospitals and laboratories improve productivity and optimize processes.
The collaborative effort between ABB and VEI, brings this concept to reality in the biopharma industry, advancing public health care and safety, it said. Implementation of this process will support quality, capacity, and cost of operations improvements within the industry.
Executives responses
“We are very happy to work together with Vyripharm to advance and automate its quality process,” said Dr. Jose Collados, line manager for ABB Life Sciences and Healthcare Robotic Solutions. “ABB’s automated solutions will enhance process productivity and sample traceability which, when combined with Vyripharm’s process and software, will improve productivity and optimize processes, substantively advancing the future of patient care.”
“The rapid growth of the biopharma supply chain has produced a need for standardized testing to assure that the methods and instrumentation used in the testing process produce equivalent results across different laboratories. VEI has developed a process and protocol to achieve that goal,” said John W. Shadle, RPh, managing director, QA/QC of VEI. “We look forward to working with ABB to bring this concept to fruition, and to make it available for use throughout the U.S. and the world.”
“With new upcoming legislation being submitted in Congress for review, it is critical that a solid Regulatory Framework for the testing, tracking, tracing, certification and verification of all U.S. novel pharmaceutical products be established in order to protect U.S. citizens and provide standardization throughout all points of the U.S. industry supply chain for novel pharmaceuticals,” said Dr. Elias Jackson, senior vice president of government and scientific affairs for Vyripharm Enterprises.
“ABB Life Sciences and Healthcare Solutions is the leader in the integration of automation across the Life Sciences supply chain. We are excited to partner with ABB in this effort,” he said.
Article topics
Email Sign Up
Related Research & Development News
